on NICOX (EPA:COX)
Nicox Announces Financial Stability Extension
Nicox SA has announced an extended cash runway, ensuring the funding of current operations beyond Q1 2028. As of August 31, 2026, the company reported €8.4 million in cash, a significant increase from December 2025. The anticipated U.S. NDA approval milestone for NCX 470 could extend financial viability into 2029, supplemented by potential royalties post-launch in the latter half of 2027.
The company continues to explore strategic growth opportunities, including potential collaborations. Nicox remains focused on cost management and resource optimization to support its strategic goals. A shareholder loan option from Vester Finance remains available, providing additional financial flexibility.
In management changes, Doug Hubatsch transitions to Chief Scientific Advisor, while Siobhan Garbutt takes over clinical development leadership, enhancing Nicox's capability to navigate future growth opportunities.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NICOX news